Francesca Barone
Chief Tech/Sci/R&D Officer bij CANDEL THERAPEUTICS, INC.
Vermogen: 294 918 $ op 31-03-2024
Profiel
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 28-11-2023 | 186 657 ( 0.65% ) | 294 918 $ | 31-03-2024 |
Actieve functies van Francesca Barone
| Bedrijven | Functie | Begin |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-11-2020 |
Eerdere bekende functies van Francesca Barone
| Bedrijven | Functie | Einde |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-11-2020 |
| University of Birmingham | Corporate Officer/Principal | 01-05-2019 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Opleiding van Francesca Barone
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
